Alveron Pharma raises a further EUR 3.9 million to progress first in class cyclodextrin drug
Alveron Pharma BV (Nijmegen, The Netherlands) has raised a further EUR 3.9 million to fund the continued development of OKL-1111,
A forum for researchers, students and applicants in the field of cyclodextrin technology
Alveron Pharma BV (Nijmegen, The Netherlands) has raised a further EUR 3.9 million to fund the continued development of OKL-1111,
The intermolecular interactions between the cationic per-6-amino-b-CD with the highly anionic heparin analogue anticoagulant fondaparinux were studied at two different
Vitamin D deficiency or insufficiency is very common in the general population as well as in patients with COVID-19. It